Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characteristic molecular signature of pericardial effusion identifies malignant cancer in pericardial disorder patients

ABSTRACT: Characteristic molecular signature of pericardial effusion identifies malignant cancer in pericardial disorder patients

PROVIDER: PRJNA485430 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Characteristic molecular signature of pericardial effusion identifies malignant cancer in pericardial disorder patients

Project description:we examined 24 pericardial effusion patients and obtained pericardial fluid. To identify novel biomarker for detection cancer, detected transcriptome-based molecualr signature of compare pathologic cancer patients and non-cancer patients.

2019-12-31 | GSE118385 | GEO

Unbiased undepleted malignant pleural effusion proteomics study

Project description:Pleural effusion (PE) occurs as a consequence of various pathologies. Malignant effusion due to lung cancer is one of the most frequent causes. Methods for accurate differentiation of malignant from benign PE cases are an unmet clinical need. Proteomics profiling of PE has shown promising results. However, mass spectrometry (MS) analysis typically involves the tedious elimination of abundant proteins before analysis, and clinical annotation of proteomics profiled cohorts is limited. In this study, PE from 97 patients was investigated by applying label-free state-of-the-art liquid chromatography-mass spectrometry (LC-MS) to find potential novel biomarkers that correlate with immunohistochemistry assessment of tumor biopsy or survival data. The data set consists of 214 LC-MS runs.

2022-10-14 | PXD035884 | Pride

Microarray expression profiles of circular RNA in malignant pleural effusion

Project description:To explore the expression pattern of circular RNAs (circRNAs) and their biological functions in malignant pleural effusion, we surveyed the circRNA expression profiles of 3 lung adenocarcinoma-associated malignant pleural effusion (LA-MPE) and 3 tuberculous pleural effusion (TPE) from clinical patients using Clariom D human microarray.

2023-05-01 | GSE122427 | GEO

Efferocytosis fuels malignant pleural effusion through TIMP1

Project description:Efferocytosis fuels malignant pleural effusion through TIMP1

| PRJNA723335 | ENA

The RNA Sequencing of B Cells in malignant pleural effusion

Project description:By using RNA sequencing plat, we employed malignant pleural effusion as research model to performed RNA sequencing of naïve B cells and Breg cells in the immune microenvironment of MPE.

2022-12-14 | GSE220822 | GEO

CircRNA_051778 in Exosomes as A Potential Biomarker for Distinguishing Lung Adenocarcinoma-Associated Malignant Pleural Effusion from Tuberculous Pleural Effusion

Project description:We profiled the exosomal circRNA in lung adenocarcinoma-associated malignant (LA-MPE) and tuberculous (TPE) pleural effusion samples by circRNA microarray to determine the potential functions and diagnostic value of the differential expressed circRNAs (DECs)

2022-04-01 | GSE171540 | GEO

Malignant Pericardial Effusion: A Systematic Review.

Project description:BackgroundMalignant pericardial effusion (Eff) is often asymptomatic and has an unknown prevalence, due to its occult presentation. The condition often is identified postmortem on autopsy, and it is associated with a poor prognosis. Given the late presentation of malignant pericardial Effs, a minimal volume of literature has examined the epidemiology, clinical characteristics, and outcomes of these complex patients. We conducted a systematic review to advance present understanding of this condition.MethodsA search of 4 databases resulted in 41 case reports meeting criteria. Inclusion criteria were being a patient aged > 18 years who presented with pericardial Eff in the setting of malignancy. Intervention was medical and/or surgical therapy, and the outcome was mortality.ResultsFor the 41 patients included, the median age was 54 years, and the majority were male patients (58%). Dyspnea was the leading symptom (90%), and cardiac tamponade was present in 78% of cases. Common cancers included lung, gastrointestinal, and renal neoplasms (59%). Pericardiocentesis occurred in 98% of cases, with a median fluid extraction volume of 1000 mL. Death occurred in 44%, primarily due to disease progression and/or metastasis.ConclusionsThis study presents the largest systematic review on malignancy-induced pericardial Effs to date. Notably, solid tumours, and specifically lung adenocarcinomas, are common culprits. Malignant pericardial Effs are often severe, with a majority of patients presenting with cardiac tamponade. Overall, treatment options are limited, and the associated mortality rate is high.

| S-EPMC11357784 | biostudies-literature

The Single Cell Sequencing of Immune Cells in malignant pleural effusion

Project description:By using 10X genomics single-cell RNA sequencing plat, we employed malignant pleural effusion as research model to performed single-cell RNA sequencing to map the immune microenvironment of MPE. Meanwhile we performed TCR and BCR sequencing for immune receptor repertoire analysis.

2021-10-15 | GSE185058 | GEO

Tumor-mast cell transcriptional interactions in malignant pleural effusion

Project description:Tumor-mast cell transcriptional interactions in malignant pleural effusion

| PRJNA251530 | ENA

Survival and pleurodesis response markers in malignant pleural effusion – The PROMISE study

Project description:Background: Malignant pleural effusion (MPE) is a common condition that indicates advanced malignancy, incurability and short life expectancy. While MPE incidence is increasing worldwide, prognostic biomarkers to plan treatment and to understand the underlying mechanisms of disease progression remain unidentified. Objective: To discover, validate, and prospectively assess biomarkers of survival and pleurodesis response in MPE. To combine clinical, radiologic, and pleural fluid biologic parameters in order to build a score that forecasts survival. Conclusions: The PROMISE score is the first prospectively validated prognostic model for MPE that combines biological and clinical parameters to accurately estimate 3-month mortality.

2018-07-17 | PXD008682 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data